Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells
Curation statements for this article:-
Curated by eLife
Evaluation Summary:
Patients with Gaucher disease can have significant and crippling neurological manifestations. The study uses novel mouse models of neurodegeneration associated with glucocerebrosidase 1 (GBA1) deficiency. It provides a detailed analysis of the alterations caused by targeted deletion of GBA1, including cellular, genetic and metabolic alterations in neurons, microglia, and infiltrating immune cells. The work defines novel mechanisms driving neuroinflammation in neuronopathic Gaucher disease.
(This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
- Immunology and Inflammation (eLife)
Abstract
Background
Neuronopathic Gaucher Disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in Gba , and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features, however the role of Gba in individual cell types and involvement of microglia, blood derived macrophages and immune infiltrates in nGD pathology remains enigmatic.
Methods
Here, using single cell resolution of mouse nGD brains, we found induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons.
Results
Targeted rescue of Gba in microglia and in neurons, respectively in Gba deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), concomitant with amelioration of neuroinflammation, reduced level of serum neurofilament light chain (Nf-L) and improved survival. The levels of bioactive lipid, GlcSph was strongly correlated with serum Nf-L and ApoE in nGD mouse models as well as GD patients. Gba rescue in microglia/macrophage compartment prolonged survival, that was further enhanced upon treatment with brain permeant inhibitor of glucosylceramide synthase, effects mediated via improved glycosphingolipid homeostasis and reversal of neuroinflammation involving activation of microglia, brain macrophages and NK cells.
Conclusions
Together, our study delineates individual cellular effects of Gba deficiency in nGD brains, highlighting the central role of neuroinflammation driven by microglia activation and the role of brain permeant small molecule glucosylceramide inhibitor in reversing complex multidimensional pathophysiology of nGD. Our findings advance disease biology whilst identifying compelling biomarkers of nGD to improve patient management, enrich clinical trials and illuminate therapeutic targets.
Funding:
Research grant from Sanofi Genzyme; other support includes R01NS110354.Yale Liver Center P30DK034989, pilot project grant.
Article activity feed
-
Evaluation Summary:
Patients with Gaucher disease can have significant and crippling neurological manifestations. The study uses novel mouse models of neurodegeneration associated with glucocerebrosidase 1 (GBA1) deficiency. It provides a detailed analysis of the alterations caused by targeted deletion of GBA1, including cellular, genetic and metabolic alterations in neurons, microglia, and infiltrating immune cells. The work defines novel mechanisms driving neuroinflammation in neuronopathic Gaucher disease.
(This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)
-
-
Reviewer #1 (Public Review):
This study by Boddupalli et al. demonstrated the roles of Gba in individual cells such as microglia, blood-derived macrophages, and astrocytes in the neuronopathic Gaucher Disease (nGD), a neurodegenerative disorder caused by biallelic mutations in Gba. The authors applied single-cell resolution of mouse nGD brains to reveal the induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons. They also found that targeted rescue of Gba in microglia or neurons, respectively in Gba deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), reduced the level of serum neurofilament light chain (Nf-L), and improved survival. Together with other related findings in this paper, this study delineated individual cellular effects of Gba …
Reviewer #1 (Public Review):
This study by Boddupalli et al. demonstrated the roles of Gba in individual cells such as microglia, blood-derived macrophages, and astrocytes in the neuronopathic Gaucher Disease (nGD), a neurodegenerative disorder caused by biallelic mutations in Gba. The authors applied single-cell resolution of mouse nGD brains to reveal the induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons. They also found that targeted rescue of Gba in microglia or neurons, respectively in Gba deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), reduced the level of serum neurofilament light chain (Nf-L), and improved survival. Together with other related findings in this paper, this study delineated individual cellular effects of Gba deficiency in nGD brains. The experiments were well designed and conducted, the results were reasonably interpreted, and the manuscript was clearly written with logical inputs.
One weak point is that it remained unclear or not addressed about the brain region or tissue-specific involvement in the observed phenotypes in this study.
-
-
Reviewer #2 (Public Review):
In this manuscript, Boddupalli et al. did a detailed analysis of the alterations caused by targeted deletion of GBA1, using new mouse models of GBA1-associated neurodegeneration. This included a study of the cellular, genetic and metabolic alterations in neurons, microglia, and infiltrating immune cells, caused by GBA1 deficiency. The work clarified some of the mechanisms driving neuroinflammation in neuronopathic Gaucher disease (nGD). The methods used, including single-cell RNA sequencing are state-of-the-art, and the data are of high quality. The results fully support the main conclusions of the paper, and the data sets will be useful to other investigators in the field.
This paper shows the deregulation of important neuroinflammatory networks at a single cell resolution level. Targeted rescue of Gba in …
Reviewer #2 (Public Review):
In this manuscript, Boddupalli et al. did a detailed analysis of the alterations caused by targeted deletion of GBA1, using new mouse models of GBA1-associated neurodegeneration. This included a study of the cellular, genetic and metabolic alterations in neurons, microglia, and infiltrating immune cells, caused by GBA1 deficiency. The work clarified some of the mechanisms driving neuroinflammation in neuronopathic Gaucher disease (nGD). The methods used, including single-cell RNA sequencing are state-of-the-art, and the data are of high quality. The results fully support the main conclusions of the paper, and the data sets will be useful to other investigators in the field.
This paper shows the deregulation of important neuroinflammatory networks at a single cell resolution level. Targeted rescue of Gba in microglia and in neurons of nGD mice reversed the buildup of glucosphingolipids with reversal of neuroinflammation. The authors also identified early biomarkers to follow disease progression and response to treatment, which were validated using sera from patients with type 3 and type 1 GD. The new markers identified included Nf-L and ApoE. Nf-L was elevated 2,000-fold in nGD mice, and there were also substantial elevations in adult GD1 patients compared to control adults. The authors also found significant differences in these disease markers between young and older GD1 patients. Nf-L and ApoE levels in the mutant mice and nGD patients were significantly reduced by brain-penetrant GluCer synthase inhibitors, further implicating elevated glucosphingolipids in the pathogenesis of GBA1-associated neurodegeneration, and validating substrate reduction as a useful therapy.
These results of this ground-breaking study are critically important for therapeutic development, as there is an unmet need to identify GD patients and GD carriers at risk for PD/LBD. In sum, the results presented are of great clinical significance.
-
-
